Share on StockTwits

DaVita HealthCare Partners (NYSE:DVA) announced its earnings results on Thursday. The company reported $0.95 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.89 by $0.06, Stock Ratings Network reports. The company had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.10 billion. During the same quarter in the prior year, the company posted $1.84 earnings per share. The company’s quarterly revenue was up 10.5% on a year-over-year basis.

Several analysts have recently commented on the stock. Analysts at Raymond James downgraded shares of DaVita HealthCare Partners from an “outperform” rating to a “market perform” rating in a research note on Monday, July 21st. They now have a $75.00 price target on the stock. On the ratings front, analysts at Zacks reiterated a “neutral” rating on shares of DaVita HealthCare Partners in a research note on Wednesday, July 16th. They now have a $77.00 price target on the stock. Finally, analysts at Jefferies Group initiated coverage on shares of DaVita HealthCare Partners in a research note on Monday, June 30th. They set a “buy” rating and a $86.00 price target on the stock. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. DaVita HealthCare Partners has a consensus rating of “Buy” and an average price target of $79.60.

Shares of DaVita HealthCare Partners (NYSE:DVA) traded down 1.23% on Thursday, hitting $70.44. 1,992,489 shares of the company’s stock traded hands. DaVita HealthCare Partners has a 1-year low of $52.75 and a 1-year high of $74.84. The stock’s 50-day moving average is $72.1 and its 200-day moving average is $68.86. The company has a market cap of $15.088 billion and a P/E ratio of 19.50.

DaVita HealthCare Partners Inc, formerly DaVita Inc, is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (NYSE:DVA).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.